Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Trading Advice for Viking Therapeutics Inc. VKTX including day trading swing trading and long term investing plans for VKTX ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...